Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.70 |
| ▸ | DRD2 | P14416 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229965 | 0.90 | HRH3 (0.70) | HRH3DRD2ALDH1A1HPGD | |
| SCHEMBL4232435 | 0.88 | DRD2 (0.65) | HRH3DRD2POLBMAPTDRD3 | |
| SCHEMBL4230533 | 0.88 | HRH3 (0.65) | HRH3DRD2ALDH1A1HPGD | |
| SCHEMBL14026354 | 0.88 | HRH3 (0.64) | HRH3DRD2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4225310 | 0.87 | HRH3 (0.64) | HRH3DRD2ALDH1A1HPGD | |
| SCHEMBL4225264 | 0.87 | HRH3 (0.72) | HRH3DRD2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4228880 | 0.86 | HRH3 (0.70) | HRH3DRD2ALDH1A1HPGD | |
| SCHEMBL4224193 | 0.86 | HRH3 (0.61) | HRH3DRD2 | |
| SCHEMBL4234291 | 0.86 | HRH3 (0.62) | HRH3DRD2MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4233278 | 0.85 | HRH3 (0.61) | HRH3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042862-A1 | NOVEL COMPOUNDS | BEST DESMOND JOHN | 2009-02-12 | — | — | US | claimed |
| US-7446103-B2 | Bicyclic benzamide compound as histamine H3 receptor ligand useful in the treatment of neurological diseases | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | claimed |
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | GLAXO GROUP LIMITED (GB) | 2007-05-10 | — | — | US | claimed |
| EP-1554243-B1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LTD (GB) | 2006-11-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105838-A1 | Bicyclic Benzamide Compoundssa as Histamine H3 Receptor Ligand Useful in the Treatment of Neurological Diseases | HRH3, HRH4, HRH1 | HRH3 1/4885DRD2 401/4885POLB 3588/4885 |
| US-20090042862-A1 | NOVEL COMPOUNDS | GRIN2C, GRIN2A, GRIN2B | HRH3 512/4885DRD2 96/4885POLB 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.